Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

21.72
+0.77003.68%
Post-market: 21.71-0.0100-0.05%19:44 EDT
Volume:1.62M
Turnover:34.84M
Market Cap:2.18B
PE:-4.70
High:21.95
Open:21.00
Low:20.55
Close:20.95
Loading ...

Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics today

TIPRANKS
·
26 Mar

Cathie Wood Bets on Baidu as Chinese AI Buzz Intensifies, Ark Loads up on $12.4 Million Worth of Stock

Benzinga
·
25 Mar

CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?

Zacks
·
19 Mar

Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years?

Insider Monkey
·
16 Mar

Beam, Unity, Checkpoint, Inuvo, Ocular: Trending by Analysts

TIPRANKS
·
15 Mar

Beam Therapeutics Inc : Citigroup Raises Target Price to $64 From $56

THOMSON REUTERS
·
13 Mar

BEAM Down Despite Positive Initial Data From Genetic Disorder Study

Zacks
·
12 Mar

Beam Therapeutics Inc : Jonestrading Raises to Buy From Hold

THOMSON REUTERS
·
11 Mar

Cathie Wood’s ARK Investment buys 485K shares of Beam Therapeutics today

TIPRANKS
·
11 Mar

Beam Therapeutics Raised to Sector Outperform From Sector Perform by Scotiabank

Dow Jones
·
11 Mar

Beam Therapeutics Raised to Buy From Hold by Jones Trading

Dow Jones
·
11 Mar

Beam Therapeutics Shares Drop After $500M Offering Prices

Dow Jones
·
11 Mar

Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright

TIPRANKS
·
10 Mar

Promising Phase 1/2 Trial Results for Beam Therapeutics’ BEAM-302 Bolster Confidence and Support $80 Price Target

TIPRANKS
·
10 Mar

Scotiabank Upgrades Beam Therapeutics to Sector Outperform From Sector Perform, $40 Price Target

MT Newswires Live
·
10 Mar

Beam Therapeutics’ BEAM-302 Shows Promising Phase I/II Results, Earning Buy Rating from Analyst

TIPRANKS
·
10 Mar

Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now?

Insider Monkey
·
10 Mar

Beam Therapeutics Says Initial Data Show BEAM-302 Increases Alpha-1 Antitrypsin Protein

MT Newswires Live
·
10 Mar

Beam Therapeutics Prices $500 Million Share, Warrant Offering

MT Newswires Live
·
10 Mar

BUZZ-Beam Therapeutics rises on early-stage trial results for gene editing therapy

Reuters
·
10 Mar